C5 and Fatigable weakness: Background and aims: In the Phase 3 RAISE study (NCT04115293), zilucoplan, a complement component 5 inhibitor, demonstrated clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG‐ADL) and Quantitative Myasthenia Gravis (QMG) total scores versus placebo in patients with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis.